Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 31, 2006
Business Overview: The Company manufactures laboratory furniture and equipment. Operations are divided into domestic and international segments, with significant growth noted in Asian subsidiaries.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 31, 2006 | 6 Months Ended Oct 31, 2006 |
|---|---|---|
| Net Sales | $21,385 | $40,679 |
| Gross Profit | $4,080 | $7,208 |
| Gross Margin | 19.1% | 17.7% |
| Operating Earnings | $1,181 | $1,672 |
| Net Earnings | $569 | $702 |
| Diluted EPS | $0.23 | $0.28 |
| Cash from Operations (6mo) | $959 | |
| Short-term Borrowings | $8,137 | |
| Working Capital | $11,619 |
Material Changes vs. Prior Period
- Sales Decline: Net sales decreased 4.2% for the quarter and 4.6% for the six-month period compared to the prior year. Domestic sales declined 16% (quarter) and 12.3% (six months) due to pharmaceutical companies shifting construction budgets overseas and project delays.
- International Growth: Sales from Asian subsidiaries doubled in the quarter and increased 66.5% for the six-month period, partially offsetting domestic declines.
- Margin Expansion: Gross profit margins improved to 19.1% (quarter) and 17.7% (six months) from 15.6% and 16.1% in the prior year, driven by manufacturing efficiencies from previous capital expenditures.
- Operating Earnings: Operating earnings increased significantly to $1.181 million for the quarter (from $0.532 million) and $1.672 million for six months (from $1.882 million). The prior year's six-month figure included a one-time $884,000 gain from the sale of a Texas property.
- Interest Expense: Interest expense rose to $195,000 (quarter) and $382,000 (six months) due to higher interest rates and increased borrowing levels.
Guidance, Outlook, and Risks
- Outlook: Management expects the last six months of fiscal year 2007 to be profitable and significantly improved over the same period last year.
- Order Backlog: Total order backlog stood at $34.3 million as of October 31, 2006, down slightly from $36.5 million at July 31, 2006.
- Accounting Changes: The Company adopted SFAS No. 123(R) effective May 1, 2006, resulting in share-based compensation expense of $1.148 million for the six months ended October 31, 2006. Expected expense for fiscal year 2007 is $2.298 million.
- Pension Impact: Adoption of SFAS No. 158 is expected to result in a $2.1 million charge to comprehensive income at April 30, 2007, reducing prepaid pension costs.
- Risks: Demand is sensitive to laboratory construction project volumes. Earnings are exposed to rising raw material costs (stainless steel, wood, epoxy resin) and the ability to pass these costs to customers.
Investor Verification Checklist
- Domestic Market Exposure: Verify the extent of the 16% domestic sales decline and the sustainability of the shift of pharmaceutical construction budgets to overseas markets.
- Debt Servicing: Confirm the status of the $8.1 million outstanding on the revolving credit facility, which expires December 31, 2006, and the terms of its expected extension.
- Margin Sustainability: Assess whether the improved gross margins (19.1%) can be maintained given rising raw material costs mentioned in the risk factors.
- Accounting Adjustments: Review the impact of the new share-based compensation rules (SFAS 123(R)) and the upcoming SFAS 158 pension charge on future earnings and equity.
- Order Backlog: Monitor the trend of the $34.3 million backlog to gauge future revenue visibility.